Heartflow (NASDAQ:HTFL) Major Shareholder Bain Capital Life Sciences Inv Sells 797,133 Shares

Heartflow, Inc. (NASDAQ:HTFL) major shareholder Bain Capital Life Sciences Inv sold 797,133 shares of Heartflow stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $29.37, for a total value of $23,411,796.21. Following the completion of the transaction, the insider directly owned 9,396,915 shares in the company, valued at $275,987,393.55. This represents a 7.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Bain Capital Life Sciences Inv also recently made the following trade(s):

• On Thursday, April 30th, Bain Capital Life Sciences Inv sold 948,757 shares of Heartflow stock. The shares were sold at an average price of $29.23, for a total value of $27,732,167.11.
• On Tuesday, April 28th, Bain Capital Life Sciences Inv sold 254,110 shares of Heartflow stock. The shares were sold at an average price of $30.51, for a total value of $7,752,896.10.
• On Wednesday, February 4th, Bain Capital Life Sciences Inv sold 2,000,000 shares of Heartflow stock. The shares were sold at an average price of $28.05, for a total value of $56,100,000.00.

Heartflow Stock Up 0.8%

Shares of NASDAQ HTFL traded up $0.23 during midday trading on Thursday, hitting $29.76. The stock had a trading volume of 1,494,251 shares, compared to its average volume of 1,071,590. The company has a market capitalization of $2.55 billion and a price-to-earnings ratio of -14.95. Heartflow, Inc. has a 1-year low of $20.13 and a 1-year high of $41.22. The company has a fifty day moving average price of $26.11 and a 200 day moving average price of $29.28.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Wells Fargo & Company reduced their price objective on Heartflow from $38.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday, March 19th. Canaccord Genuity Group lifted their price objective on Heartflow from $40.00 to $43.00 and gave the company a “buy” rating in a research note on Thursday, March 19th. Finally, JPMorgan Chase & Co. reduced their price target on Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, March 19th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.67.

Hedge Funds Weigh In On Heartflow

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Staley Capital Advisers Inc. lifted its position in Heartflow by 100.0% during the 1st quarter. Staley Capital Advisers Inc. now owns 14,000 shares of the company’s stock worth $341,000 after acquiring an additional 7,000 shares in the last quarter. HB Wealth Management LLC acquired a new position in Heartflow during the 1st quarter worth approximately $613,000. Strs Ohio lifted its position in Heartflow by 35.3% during the 1st quarter. Strs Ohio now owns 4,600 shares of the company’s stock worth $112,000 after acquiring an additional 1,200 shares in the last quarter. XXEC Inc. lifted its position in Heartflow by 564.8% during the 1st quarter. XXEC Inc. now owns 278,681 shares of the company’s stock worth $6,780,000 after acquiring an additional 236,761 shares in the last quarter. Finally, TrueMark Investments LLC lifted its position in Heartflow by 1.4% during the 1st quarter. TrueMark Investments LLC now owns 26,885 shares of the company’s stock worth $654,000 after acquiring an additional 379 shares in the last quarter.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.